Management
In a randomized trial, galcanezumab (300 mg subcutaneously) administered at baseline and 1 month led to a reduction in weekly cluster headache attacks compared to placebo [PMID:31291515].
Patients receiving galcanezumab experienced a greater percentage reduction (≥50%) in weekly cluster headache attacks compared to those on placebo by week 3 [PMID:31291515].
Key Recommendations
Due to early recruitment halt, the study sample size was reduced, highlighting the need for larger trials to validate the efficacy and safety of galcanezumab [PMID:31291515]. (Evidence: Expert opinion)
References
1 Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA et al.. Trial of Galcanezumab in Prevention of Episodic Cluster Headache. The New England journal of medicine 2019. link
1 papers cited of 3 indexed.